Steve Cohen's Point72 Asset Management has liquidated its entire position in Dianthus Therapeutics, a clinical-stage biotechnology company. According to regulatory filings, the firm sold all 643,600 of its shares, which were previously valued at approximately $54.01 million. It is important to note that this trade was disclosed in a quarterly 13F filing, which reports positions held as of June 30, 2026, meaning the transactions occurred sometime during the second quarter.
Dianthus Therapeutics focuses on developing therapies for severe autoimmune diseases and is advancing several clinical trials for its antibody treatment, claseprubart. During the second quarter, the company initiated a Phase 3 trial for generalized Myasthenia Gravis and reported a net loss of $50.2 million. The firm's increased R&D and administrative expenses reflect its ongoing investment in its clinical development programs.